Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

These medications attach to specific sites on certain cells ... In late 2023, the FDA approved Zepbound (tirzepatide), a weekly injection, for weight loss in adults. Unlike other weight-loss ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug ... the active ingredient in Eli Lilly's weight loss drug Zepbound and diabetes treatment Mounjaro, from its shortage ...

What's behind Lilly's disappointing Q3 update? Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year ...

Recommended Videos Sales of Lilly's diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers whittled inventory they had built ...

Ricks, Lilly chair and CEO. "While the growth of Mounjaro and Zepbound is impressive, we are equally proud of the 17% growth in non-incretin revenue, which includes our oncology, immunology and ...